Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.63 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | CLK3 | P49761 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24288708 | 1.00 | DYRK1A (0.63) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL24288618 | 0.94 | DYRK1A (0.62) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL29400664 | 0.94 | DYRK1A (0.62) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL29400241 | 0.93 | DYRK1A (0.65) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL24288469 | 0.93 | DYRK1A (0.65) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL24288507 | 0.92 | DYRK1A (0.63) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL29400310 | 0.92 | DYRK1A (0.63) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL24288870 | 0.90 | DYRK1A (0.53) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL29397772 | 0.90 | DYRK1A (0.53) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL24062932 | 0.88 | DYRK1A (0.54) | DYRK1ADYRK3CSNK1ECLK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240844-B2 | Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease | VORONOI, INC. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20220064161-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE | VORONOI, INC. (KR) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240844-B2 | Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease | CLK1, CLK2, CLK3 | DYRK1A 7/4885DYRK3 11/4885CSNK1E 100/4885 |
| US-20220064161-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE | CLK1, CLK2, CLK3 | DYRK1A 7/4885DYRK3 11/4885CSNK1E 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.